2012 - Fellow of the American Association for the Advancement of Science (AAAS)
William Plunkett mainly investigates Leukemia, Chronic lymphocytic leukemia, Biochemistry, Internal medicine and Cancer research. The concepts of his Leukemia study are interwoven with issues in Myeloid, Reactive oxygen species and Refractory. His Chronic lymphocytic leukemia research incorporates themes from Myeloid Cell Leukemia Sequence 1 Protein and Programmed cell death.
His Biochemistry study integrates concerns from other disciplines, such as Molecular biology and Deoxycytidine kinase. William Plunkett has researched Internal medicine in several fields, including Gastroenterology, Surgery and Oncology. His studies deal with areas such as Cyclin-dependent kinase 9, Apoptosis, Immunology, Histone H1 and Chromatin remodeling as well as Cancer research.
William Plunkett mostly deals with Leukemia, Internal medicine, Cancer research, Chronic lymphocytic leukemia and Fludarabine. His biological study spans a wide range of topics, including Myeloid and Pharmacology. He combines subjects such as Gastroenterology, Surgery and Oncology with his study of Internal medicine.
His Cancer research study also includes
His scientific interests lie mostly in Cancer research, Chronic lymphocytic leukemia, Internal medicine, Cytarabine and Ibrutinib. His Cancer research research is multidisciplinary, relying on both Leukemia, Immunology, Histone deacetylase, DNA repair and Sapacitabine. His research in Chronic lymphocytic leukemia intersects with topics in Cancer, Cytotoxic T cell, Kinase and eIF4A.
His Internal medicine study combines topics in areas such as Gastroenterology, Surgery and Oncology. His work carried out in the field of Cytarabine brings together such families of science as Phases of clinical research, DNA damage and Transplantation. His work deals with themes such as Chemoimmunotherapy, Rituximab and [email protected], which intersect with Fludarabine.
Internal medicine, Chronic lymphocytic leukemia, Cancer research, Ibrutinib and Leukemia are his primary areas of study. As part of the same scientific family, he usually focuses on Internal medicine, concentrating on Oncology and intersecting with Deoxycytidine, Gemcitabine and Pancreatic cancer. His research in Chronic lymphocytic leukemia tackles topics such as Surgery which are related to areas like Rituximab.
William Plunkett interconnects Chemotherapy, Cyclin-dependent kinase, Immunology, KRAS and Adipose tissue in the investigation of issues within Cancer research. The various areas that William Plunkett examines in his Leukemia study include Cyclin-dependent kinase 9, Tyrosine kinase, Histone deacetylase, Myeloid leukemia and Gene silencing. His Fludarabine research includes themes of Gastroenterology, Cytarabine and Chemoimmunotherapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
Kenneth P. Olive;Michael A. Jacobetz;Christian J. Davidson;Aarthi Gopinathan;Aarthi Gopinathan.
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
Michael J. Keating;Susan O'Brien;Maher Albitar;Susan Lerner.
Journal of Clinical Oncology (2005)
Action of 2',2'-difluorodeoxycytidine on DNA synthesis.
Peng Huang;Sherri Chubb;Sherri Chubb;Larry W. Hertel;Gerald B. Grindey.
Cancer Research (1991)
Superoxide dismutase as a target for the selective killing of cancer cells
Peng Huang;Li Feng;Elizabeth A. Oldham;Michael J. Keating.
Gemcitabine : metabolism, mechanisms of action, and self-potentiation
W. Plunkett;Peng Huang;Yi-Zheng Xu;V. Heinemann.
Seminars in Oncology (1995)
Comparison of the Cellular Pharmacokinetics and Toxicity of 2′,2′-Difluorodeoxycytidine and 1-β-d-Arabinofuranosylcytosine
Volker Heinemann;Larry W. Hertel;Gerald B. Grindey;William K Plunkett.
Cancer Research (1988)
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia
M. J. Keating;Hagop M Kantarjian;M. Talpaz;J. Redman.
Inhibition of Mitochondrial Respiration A NOVEL STRATEGY TO ENHANCE DRUG-INDUCED APOPTOSIS IN HUMAN LEUKEMIA CELLS BY A REACTIVE OXYGEN SPECIES-MEDIATED MECHANISM
Helene Pelicano;Li Feng;Yan Zhou;Jennifer S. Carew.
Journal of Biological Chemistry (2003)
Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic Adenocarcinoma
Margaret Tempero;William Plunkett;Veronique Ruiz Van Haperen;John Hainsworth.
Journal of Clinical Oncology (2003)
Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.
V. Heinemann;Yi-Zheng Xu;S. Chubb;A. Sen.
Molecular Pharmacology (1990)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: